CYBIN INC.
CYBIN INC. (HELP): 2 pipeline candidates · 3 upcoming catalysts · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
0% dilution
Lead: Phase 3
2 candidates
3 upcoming, next in ~75d
N/A
A transparent, data-derived signal for CYBIN INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$204.6M
Cash
$135.0M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (2 candidates)
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
79
Total value held
$92.0M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 3,832,843 | $18.4M |
| millennium management llc | 2,415,841 | $11.6M |
| acorn capital advisors, llc | 1,540,266 | $7.4M |
| eventide asset management, llc | 1,410,815 | $6.8M |
| deep track capital, lp | 1,313,137 | $6.3M |
| morgan stanley | 1,025,318 | $4.9M |
| sphera funds management ltd. | 987,090 | $4.7M |
| citadel advisors llc | 915,647 | $4.4M |
| adage capital partners gp, l.l.c. | 700,000 | $3.4M |
| dcf advisers, llc | 691,988 | $3.3M |
Showing top 10 of 79 institutional holders of CYBIN INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CYBIN INC.'s pipeline?
CYBIN INC. (HELP) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CYBIN INC.'s lead drug candidate?
CYBIN INC.'s most advanced tracked candidate is cyb003 (Phase 3) for Major Depressive Disorder; Major Depressive Disorder (MDD).
What is CYBIN INC.'s next catalyst?
CYBIN INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Co" — expected September 1, 2026.
What is CYBIN INC.'s market capitalization?
CYBIN INC.'s market capitalization is approximately $204.6M.
Who is the CEO of CYBIN INC.?
Mr. Eric So L.L.B. is the chief executive officer of CYBIN INC. (HELP).
Get the full picture on CYBIN INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.